NCT03010423终止4 期
An Interventional, Pilot Study to Evaluate the Efficacy of Oral Nicorandil on Improving Microvascular Function in Female Non-obstructive CAD Patients (SPET Study)
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 终止
- 入组人数
- 8
- 试验地点
- 1
- 主要终点
- Change From Baseline in Myocardial Blood Flow Reserve (MFR) by Stress Positron Emission Tomography (PET) at Week 12
研究概览
简要总结
The study is a single-center, interventional, pilot study to evaluate the improvement of microvascular function by positron emission tomography (PET) after twelve-week treatment of oral nicorandil in female non-obstructive CAD Participants.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究组 & 干预措施
Nicorandil
Experimental
干预措施: Nicorandil (Drug)
结局指标
主要结局
Change From Baseline in Myocardial Blood Flow Reserve (MFR) by Stress Positron Emission Tomography (PET) at Week 12
时间窗: Baseline, Week 12
Myocardial blood flow reserve is a measure of endothelial function measured by positron emission tomography.
次要结局
- Change From Baseline in Myocardial Blood Flow (MBF) by Rest Positron Emission Tomography (PET) at Week 12(Baseline, Week 12)
- Change From Baseline in Myocardial Blood Flow (MBF) by Stress Positron Emission Tomography (PET) at Week 12(Baseline, Week 12)
- Change From Baseline in Ejection Fraction at Week 12(Baseline, Week 12)
- Change From Baseline in Left Ventricular End-Systolic Dimension (LVESD) at Week 12(Baseline, Week 12)
- Change From Baseline in Left Ventricular Wall Thickness at Week 12(Baseline, Week 12)
- Change From Baseline in Cardiac Diastolic Function: Early [E] to Late [A] Ventricular Filling Velocities (E/A) Ratio at Week 12(Baseline, Week 12)
- Change From Baseline in Seattle Angina Questionnaire(SAQ) Score at Week 12(Baseline, Week 12)
研究者
研究点 (1)
Loading locations...
相似试验
终止
不适用
Examining the Effects of Neuromodulation on Glucose Metabolism in Type 2 DiabetesType 2 DiabetesNCT02130401Scion NeuroStim6
已完成
1 期
Allogeneic ABCB5-positive Stem Cells for Treatment of Epidermolysis BullosaRecessive Dystrophic Epidermolysis BullosaNCT03529877RHEACELL GmbH & Co. KG16
已完成
1 期
Allogeneic ABCB5-positive Stem Cells for Treatment of CVUSkin Ulcer Venous Stasis ChronicNCT03257098RHEACELL GmbH & Co. KG31
进行中（未招募）
1 期
Allogeneic ABCB5-positive Limbal Stem Cells for Treatment of LSCDLimbal Stem Cell DeficiencyNCT03549299RHEACELL GmbH & Co. KG16
终止
1 期
Clinical Trial to Investigate Efficacy and Safety of the IMP in Patients With Non Healing Wounds Originating From UlcersSkin Ulcer Venous Stasis ChronicNCT02742844RHEACELL GmbH & Co. KG13